Management of AML Beyond “3 + 7” in 2019
- https://doi.org/10.2991/chi.d.190316.001How to use a DOI?
- Acute myeloid leukemia; Targeted agents; FLT3; bcl-2; IDH1; IDH2
The therapeutic paradigm for treatment of acute myeloid leukemia (AML) is rapidly changing with the advent of a new generation of drugs targeting diverse aspects of leukemogenesis. Whereas standard treatment for AML until recently consisted of a classic chemotherapy backbone, the incorporation of novel agents targeting pathogenic mutations, myeloid surface markers, and apoptosis-related proteins may become a reality in the next few years. In this review, we outline the therapeutic landscape of recently approved novel agents for AML, including FLT3 inhibitors, isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors, Bcl-2 antagonists, hedgehog signaling inhibitors, and immunotherapy-based approaches. Some of the future challenges in the field would be to delineate which specific patient subsets derive the most clinical benefit from a given novel agent and, furthermore, which drug combinations will yield the maximal antileukemia effect without increased toxicity. To this end, it is expected that advances in genomic and epigenomic classification of AML will facilitate a rational and optimal choice of these novel agents for AML patients.
- © 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - JOUR AU - Jonathan Canaani PY - 2019 DA - 2019/03/18 TI - Management of AML Beyond “3 + 7” in 2019 JO - Clinical Hematology International SP - 10 EP - 18 VL - 1 IS - 1 SN - 2590-0048 UR - https://doi.org/10.2991/chi.d.190316.001 DO - https://doi.org/10.2991/chi.d.190316.001 ID - Canaani2019 ER -